Trial · NCT03274076
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experience Grade 3 or Higher Adverse Events That Occur at or Before Week 24 | Tofacitinib Double Blind 0-24 Weeks | 0 | Participants | ||
| Number of Participants Who Experience Grade 3 or Higher Adverse Events That Occur at or Before Week 24 | Placebo Double Blind 0-24 Weeks | 0 | Participants | ||
| Number of Grade 3 (Severe) or Higher Adverse Events That Occur Throughout the Study | Tofacitinib Double Blind 0-24 Weeks | Week 12 | 0 | Adverse Events | |
| Number of Grade 3 (Severe) or Higher Adverse Events That Occur Throughout the Study | Placebo Double Blind 0-24 Weeks | Week 12 | 0 | Adverse Events | |
| Number of Grade 3 (Severe) or Higher Adverse Events That Occur Throughout the Study | Tofacitinib Double Blind 0-24 Weeks | Week 24 | 0 | Adverse Events | |
| Number of Grade 3 (Severe) or Higher Adverse Events That Occur Throughout the Study | Placebo Double Blind 0-24 Weeks | Week 24 | 0 | Adverse Events | |
| Number of Grade 3 (Severe) or Higher Adverse Events That Occur Throughout the Study | Tofacitinib to Tofacitinib Open Label 24-48 Weeks | Week 36 | 2 | Adverse Events | |
| Number of Grade 3 (Severe) or Higher Adverse Events That Occur Throughout the Study | Placebo to Tofacitinib Open Label 24-48 Weeks | Week 36 | 0 | Adverse Events | |
| Number of Grade 3 (Severe) or Higher Adverse Events That Occur Throughout the Study | Tofacitinib to Tofacitinib Open Label 24-48 Weeks | Week 48 | 1 | Adverse Events | |
| Number of Grade 3 (Severe) or Higher Adverse Events That Occur Throughout the Study | Placebo to Tofacitinib Open Label 24-48 Weeks | Week 48 | 1 | Adverse Events | |
| Number of Grade 2 (Moderate) or Higher Adverse Events That Occur Throughout the Study | Tofacitinib Double Blind 0-24 Weeks | Week 12 | 7 | Adverse Events | |
| Number of Grade 2 (Moderate) or Higher Adverse Events That Occur Throughout the Study | Placebo Double Blind 0-24 Weeks | Week 12 | 5 | Adverse Events | |
| Number of Grade 2 (Moderate) or Higher Adverse Events That Occur Throughout the Study | Tofacitinib Double Blind 0-24 Weeks | Week 24 | 5 | Adverse Events | |
| Number of Grade 2 (Moderate) or Higher Adverse Events That Occur Throughout the Study | Placebo Double Blind 0-24 Weeks | Week 24 | 5 | Adverse Events | |
| Number of Grade 2 (Moderate) or Higher Adverse Events That Occur Throughout the Study | Tofacitinib to Tofacitinib Open Label 24-48 Weeks | Week 36 | 14 | Adverse Events | |
| Number of Grade 2 (Moderate) or Higher Adverse Events That Occur Throughout the Study | Placebo to Tofacitinib Open Label 24-48 Weeks | Week 36 | 3 | Adverse Events | |
| Number of Grade 2 (Moderate) or Higher Adverse Events That Occur Throughout the Study | Tofacitinib to Tofacitinib Open Label 24-48 Weeks | Week 48 | 4 | Adverse Events | |
| Number of Grade 2 (Moderate) or Higher Adverse Events That Occur Throughout the Study | Placebo to Tofacitinib Open Label 24-48 Weeks | Week 48 | 1 | Adverse Events | |
| Number of Adverse Events of Special Interest (AESI) Throughout the Study | Tofacitinib Double Blind 0 - 24 Weeks | Week 12 | 4 | Adverse Events | |
| Number of Adverse Events of Special Interest (AESI) Throughout the Study | Placebo Double Blind 0 - 24 Weeks | Week 12 | 0 | Adverse Events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03274076/results